| Omlyclo |
761399 |
003 |
351(k) Interchangeable |
omalizumab-igec |
Injection |
Subcutaneous |
300MG/2ML (150MG/ML) |
Pre-Filled Syringe |
2025/12/01
|
CELLTRION, Inc. |
Rx |
Licensed |
omalizumab |
Xolair |
| Armlupeg |
761212 |
001 |
351(k) Biosimilar |
pegfilgrastim-unne |
Injection |
Subcutaneous |
6MG/0.6ML |
Pre-Filled Syringe |
2025/11/28
|
Lupin Limited (Biotech Division) |
Rx |
Licensed |
pegfilgrastim |
Neulasta |
| Voyxact |
761434 |
001 |
351(a) |
sibeprenlimab-szsi |
Injection |
Subcutaneous |
400MG/2ML (200MG/ML) |
Pre-Filled Syringe |
2025/11/25
|
Otsuka Pharmaceutical Company, Ltd. |
Rx |
Licensed |
N/A |
N/A |
| ITVISMA |
125856 |
001 |
351(a) |
onasemnogene abeparvovec-brve |
Injection |
Intrathecal |
4x10^13VG/ML |
Single-Dose Vial |
2025/11/24
|
Novartis Gene Therapies, Inc. |
Rx |
Licensed |
|
N/A |
| Opdivo Qvantig |
761381 |
002 |
351(a) |
nivolumab and hyaluronidase-nvhy |
Injection |
Subcutaneous |
300MG/2.5ML;5,000UNITS/2.5ML (120MG/2,000UNITS/ML) |
Single-Dose Vial |
2025/11/24
|
Bristol-Myers Squibb Company |
Rx |
Licensed |
N/A |
N/A |
| Poherdy |
761450 |
001 |
351(k) Interchangeable |
pertuzumab-dpzb |
Injection |
Intravenous |
420MG/14ML (30MG/ML) |
Single-Dose Vial |
2025/11/13
|
Shanghai Henlius Biotech, Inc. |
Rx |
Licensed |
pertuzumab |
Perjeta |
| Osvyrti |
761424 |
001 |
351(k) Interchangeable |
denosumab-desu |
Injection |
Subcutaneous |
60MG/ML |
Pre-Filled Syringe |
2025/10/29
|
Accord BioPharma Inc. |
Rx |
Licensed |
denosumab |
Prolia |
| Jubereq |
761424 |
002 |
351(k) Interchangeable |
denosumab-desu |
Injection |
Subcutaneous |
120MG/1.7ML (70MG/ML) |
Single-Dose Vial |
2025/10/29
|
Accord BioPharma Inc. |
Rx |
Licensed |
denosumab |
Xgeva |
| Blenrep |
761440 |
001 |
351(a) |
belantamab mafodotin-blmf |
For Injection |
Intravenous |
70MG |
Single-Dose Vial |
2025/10/23
|
GlaxoSmithKline LLC |
Rx |
Licensed |
N/A |
N/A |
| Eydenzelt |
761377 |
001 |
351(k) Biosimilar |
aflibercept-boav |
Injection |
Intravitreal |
2MG/0.05ML |
Single-Dose Vial |
2025/10/02
|
CELLTRION, Inc. |
Rx |
Licensed |
aflibercept |
Eylea |
| Eydenzelt |
761377 |
002 |
351(k) Biosimilar |
aflibercept-boav |
Injection |
Intravitreal |
2MG/0.05ML |
Pre-Filled Syringe |
2025/10/02
|
CELLTRION, Inc. |
Rx |
Licensed |
aflibercept |
Eylea |
| QIVIGY |
125822 |
001 |
351(a) |
Immune Globulin Intravenous, Human-kthm, 10% Solution |
Solution |
Intravenous |
5G/50ML |
Single-Dose Vial |
2025/09/26
|
Kedrion, S.p.A. |
Rx |
Licensed |
N/A |
|
| QIVIGY |
125822 |
002 |
351(a) |
Immune Globulin Intravenous, Human-kthm, 10% Solution |
Solution |
Intravenous |
10G/100ML |
Single-Dose Vial |
2025/09/26
|
Kedrion, S.p.A. |
Rx |
Licensed |
N/A |
|
| Enoby |
761439 |
001 |
351(k) Interchangeable |
denosumab-qbde |
Injection |
Subcutaneous |
60MG/ML |
Pre-Filled Syringe |
2025/09/26
|
Hikma Pharmaceuticals USA Inc. |
Rx |
Licensed |
denosumab |
Prolia |
| Xtrenbo |
761439 |
002 |
351(k) Interchangeable |
denosumab-qbde |
Injection |
Subcutaneous |
120MG/1.7ML (70MG/ML) |
Single-Dose Vial |
2025/09/26
|
Hikma Pharmaceuticals USA Inc. |
Rx |
Licensed |
denosumab |
Xgeva |
| Keytruda Qlex |
761467 |
001 |
351(a) |
pembrolizumab and berahyaluronidase alfa-pmph |
Injection |
Subcutaneous |
395MG/2.4ML; 4,800UNITS/2.4ML (165MG/2,000UNITS/ML) |
Single-Dose Vial |
2025/09/19
|
Merck Sharp & Dohme LLC |
Rx |
Licensed |
N/A |
N/A |
| Keytruda Qlex |
761467 |
002 |
351(a) |
pembrolizumab and berahyaluronidase alfa-pmph |
Injection |
Subcutaneous |
790MG/4.8ML; 9,600UNITS/4.8ML (165MG/2,000UNITS/ML) |
Single-Dose Vial |
2025/09/19
|
Merck Sharp & Dohme LLC |
Rx |
Licensed |
N/A |
N/A |
| Bosaya |
761436 |
001 |
351(k) Interchangeable |
denosumab-kyqq |
Injection |
Subcutaneous |
60MG/ML |
Pre-Filled Syringe |
2025/09/16
|
Biocon Biologics Inc. |
Rx |
Licensed |
denosumab |
Prolia |
| Aukelso |
761436 |
002 |
351(k) Interchangeable |
denosumab-kyqq |
Injection |
Subcutaneous |
120MG/1.7ML (70MG/ML) |
Single-Dose Vial |
2025/09/16
|
Biocon Biologics Inc. |
Rx |
Licensed |
denosumab |
Xgeva |
| Skyrizi |
761105 |
007 |
351(a) |
risankizumab-rzaa |
Injection |
Subcutaneous |
180MG/1.2ML (150MG/ML) |
Pre-Filled Syringe |
2025/09/03
|
AbbVie Inc. |
Rx |
Licensed |
N/A |
N/A |